hyoscyamine has been researched along with rosiglitazone in 2 studies
Studies (hyoscyamine) | Trials (hyoscyamine) | Recent Studies (post-2010) (hyoscyamine) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
---|---|---|---|---|---|
99 | 1 | 55 | 4,749 | 556 | 1,818 |
Protein | Taxonomy | hyoscyamine (IC50) | rosiglitazone (IC50) |
---|---|---|---|
CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
Bile salt export pump | Homo sapiens (human) | 4.5853 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
2 other study(ies) available for hyoscyamine and rosiglitazone
Article | Year |
---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |